{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Pan S"],"pubmed_abstract":["<h4>Background</h4>Immune checkpoint inhibitors have proven efficacy against hepatitis B-virus positive hepatocellular. However, Immunotherapy-related adverse reactions are still a major challenge faced by tumor immunotherapy, so it is urgent to establish new methods to effectively predict immunotherapy-related adverse reactions.<h4>Objective</h4>Multi-machine learning model were constructed to screen the risk factors for irAEs in ICIs for the treatment of HBV-related hepatocellular and build a prediction model for the occurrence of clinical IRAEs.<h4>Methods</h4>Data from 274 hepatitis B virus positive tumor patients who received PD-1 or/and CTLA4 inhibitor treatment and had immune cell detection results were collected from Henan Cancer Hospital for retrospective analysis. Models were est"],"journal":["Frontiers in immunology"],"pagination":["1516524"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11807960"],"repository":["biostudies-literature"],"pubmed_title":["Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning."],"pmcid":["PMC11807960"],"pubmed_authors":["Pan S","Wang Z"],"additional_accession":[]},"is_claimable":false,"name":"Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning.","description":"<h4>Background</h4>Immune checkpoint inhibitors have proven efficacy against hepatitis B-virus positive hepatocellular. However, Immunotherapy-related adverse reactions are still a major challenge faced by tumor immunotherapy, so it is urgent to establish new methods to effectively predict immunotherapy-related adverse reactions.<h4>Objective</h4>Multi-machine learning model were constructed to screen the risk factors for irAEs in ICIs for the treatment of HBV-related hepatocellular and build a prediction model for the occurrence of clinical IRAEs.<h4>Methods</h4>Data from 274 hepatitis B virus positive tumor patients who received PD-1 or/and CTLA4 inhibitor treatment and had immune cell detection results were collected from Henan Cancer Hospital for retrospective analysis. Models were est","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T11:57:12.972Z","creation":"2025-04-04T11:57:12.972Z"},"accession":"S-EPMC11807960","cross_references":{"pubmed":["39931579"],"doi":["10.3389/fimmu.2024.1516524"]}}